Role of VEGF/VEGFR autocrine in mediating EGFR TKI resistance in non-small cell lung cancer

被引：1
|
作者：
Osude, Chike [1 ]
Lin, Leo [1 ]
Foster, Brad [1 ]
Puri, Neelu [1 ]
机构：
[1] Univ Illinois, Coll Med Rockford, Rockford, IL USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2595
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
    Osude, Chike
    Lin, Leo
    Patel, Meet
    Eckburg, Adam
    Berei, Joseph
    Kuckovic, Adijan
    Dube, Namrata
    Rastogi, Aayush
    Gautam, Shruti
    Smith, Thomas J.
    Sreenivassappa, Shylendra B.
    Puri, Neelu
    CELLS, 2022, 11 (10)
  • [2] Role of AKT3 in EGFR-TKI resistance of non-small cell lung cancer.
    Huang, Shih-Hsiang
    Shih, Jin-Yuan
    Chen, Ching-Chow
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 55 - 55
  • [3] Acquired resistance of non-small cell lung cancer to EGFR-TKI: Role of AKT3.
    Huang, Shih-Hsiang
    Shih, Jin-Yuan
    Chen, Ching-Chow
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 55 - 56
  • [4] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Apatinib Combined with EGFR - TKI in Treating Advanced Non-Small Cell Lung Cancer with EGFR - TKI Resistance (Data Updated)
    Tian, R.
    Song, X.
    Guo, Y.
    Zhang, X.
    Guo, W.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S571 - S571
  • [6] EGFR TKI combination with immunotherapy in non-small cell lung cancer
    Ahn, Myung-Ju
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 465 - 469
  • [7] Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
    Gao, J.
    Li, H. -R.
    Jin, C.
    Jiang, J. -H.
    Ding, J. -Y.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (10): : 1287 - 1301
  • [8] Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer
    Fei Zhou
    Caicun Zhou
    Oncology and Translational Medicine, 2015, 1 (01) : 20 - 25
  • [9] VEGF is an autocrine survival factor in non-small cell lung cancer
    Barr, M.
    Gately, K.
    O'Byrne, K. J.
    LUNG CANCER, 2011, 71 : S2 - S2
  • [10] Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
    J. Gao
    H.-R. Li
    C. Jin
    J.-H. Jiang
    J.-Y. Ding
    Clinical and Translational Oncology, 2019, 21 : 1287 - 1301
12345